Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.